Azitra shares are trading lower by 67.8% Wednesday morning. The company priced an underwritten public offering. Get ahead of next week’s CPI & PPI with Chris Capre’s live trading strategy session this ...

Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for ...

Azitra, Inc. (NYSE:AZTR) reported third quarter results in mid-November highlighting its $10 million raise back in July, dosing of the first patient in the Netherton syndrome trial, investigational ...

As of 10:06 am GMT-4. Market open. BRANFORD, Conn., September 06, 2024--Azitra, Inc. (NYSE American: AZTR), a precision dermatology company announced that it announced today that Travis Whitfill, COO, ...

Azitra Inc (NASDAQ:AZTR) shares are trading lower by 29% to $2.41 during Tuesday’s session after the company announced a mixed shelf offering of up to $50 million. The company says these securities ...

The average one-year price target for Azitra (NYSEAM:AZTR) has been revised to $12.23 / share. This is a decrease of 27.99% from the prior estimate of $16.98 dated September 10, 2025. The price target ...

The average one-year price target for Azitra (NYSEAM:AZTR) has been revised to $2.75 / share. This is a decrease of 77.48% from the prior estimate of $12.23 dated November 14, 2025. The price target ...

Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it will present a poster ...

Azitra Inc. Annual stock financials by MarketWatch. View the latest AZTR financial statements, income statements and financial ratios.